Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01216072 · ClinicalTrials.gov registry record · Phase 4
A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,053
- Enrollment target
NCT01216072 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,053 participants.
The verdict
NCT01216072, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,053 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.
Interventions
- DRUG Fingolimod
- DRUG Standard MS DMTs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,053 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01216072
The ClinicalTrials.gov registry entry for NCT01216072 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,053 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fingolimod is the first listed.
NCT01216072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01216072 about?
NCT01216072 is a clinical study titled "A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis". The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fi...
What is the current status of trial NCT01216072?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,053 participants. The study started on 2010-08. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01216072?
The interventions under investigation include: Fingolimod (DRUG), Standard MS DMTs (DRUG).
Who is sponsoring clinical trial NCT01216072?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.